Connor, Clark & Lunn Investment Management (CC&L)
ARRY

Connor, Clark & Lunn Investment Management (CC&L)’s Array Biopharma Inc ARRY Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-47,003
Closed -$578K – 900
2017
Q3 		$578K Sell
47,003
-93,247
-66% -$866K ﹤0.01% 619
2017
Q2 		$1.17M Buy
+140,250
New +$1.15M 0.01% 471
2016
Q1 		– Sell
-522,100
Closed -$2.2M – 940
2015
Q4 		$2.2M Sell
522,100
-212,600
-29% -$970K 0.02% 324
2015
Q3 		$3.35M Sell
734,700
-156,700
-18% -$929K 0.03% 241
2015
Q2 		$6.43M Sell
891,400
-71,700
-7% -$529K 0.06% 135
2015
Q1 		$7.1M Buy
963,100
+832,500
+637% +$5.93M 0.06% 134
2014
Q4 		$618K Buy
+130,600
New +$517K 0.01% 363

Other funds holding ARRY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s ARRY Position: Q4 2017 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Array Biopharma Inc (ARRY) in Q4 2017, closing a stake of 47,003 shares — an estimated $578K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in ARRY in Q4 2014 and held it in 7 quarters. The position peaked at $7.1M in Q1 2015. 191 funds tracked by Wall St. Rank hold ARRY as of Q4 2017.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Array Biopharma Inc position as of Q4 2017 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 47,003 Array Biopharma Inc shares in Q4 2017, an estimated $578K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Array Biopharma Inc in Q4 2014 and held it in 7 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Array Biopharma Inc position peaked at $7.1M in Q1 2015.
  • 191 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q4 2017.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q4 2017, filed 9 Feb 2018.